SEARCH

SEARCH BY CITATION

References

  • 1
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004; 39: 11471171.
  • 2
    Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 20952100.
  • 3
    Meffre C, Le Strat Y, Delarocque-Astagneau E, Meyer JF, Coste D, Steinmetz J, et al. Prevalence of hepatitis C in France, 2003-2004. J Hepatol 2006; S201A
  • 4
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 5
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 6
    McHutchinson JG, Manns M, Patel K, Lindsay KL, Poynard T, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 10611069.
  • 7
    Hadziyannis SJ, Papatheodoridis GV. Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. Expert Opin Pharmacother 2003; 4: 541551.
  • 8
    Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 24912499.
  • 9
    Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 13021311.
  • 10
    Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. HEPATOLOGY 2004; 40: 14501458.
  • 11
    Davis GL, Wong JB, McHutchinson JG, Manns M, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 645652.
  • 12
    Chapko MK, Dominitz JA. Cost-effectiveness of growth factors during hepatitis C anti-viral therapy. Aliment Pharmacol Ther 2006; 24: 10671077.
  • 13
    Thevenot T, Di Martino V, Lunel-Fabiani F, Vanlemmens C, Becker MC, Bronowicki JP, et al. Complementary treatments of chronic viral hepatitis C. Gastroenterol Clin Biol 2006; 30: 197214.
  • 14
    Bonny C, Rayssiguier R, Ughetto S, Aublet-Cuvelier B, Baranger J, Blanchet G, et al. Medical practices and expectations of general practitioners in relation to hepatitis C virus infection in the Auvergne region. Gastroenterol Clin Biol 2003; 27: 10211025.
  • 15
    Blanchet E, Defossez G, Vermeau A, Ingrand I, Silvain C, Beauchant M. Epidemiology and management of care of hepatitis C infection in the Poitou-Charentes region in 1997 and 2000. Gastroenterol Clin Biol 2003; 27: 10261030.
  • 16
    Rosenthal E, Poiree M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 18031809.
  • 17
    Winnock M, Neau D, Castera L, Viot J, Lacoste D, Pellegrin JL, et al. Hepatitis B vaccination in HIV-infected patients: a survey of physicians and patients participating in the Aquitaine cohort. Gastroenterol Clin Biol 2006; 30: 189195.
  • 18
    Talal AH, Weisz K, Hau T, Kreiswirth S, Dieterich DT. A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha. Am J Gastroenterol 2001; 96: 28022804.
  • 19
    Lunel-Fabiani F, Fouchard-Hubert I, Gergely AE. Use of erythropoietin in the treatment of anemia induced by ribavirin/interferon in patients with hepatitis C. Pathol Biol 2003; 51: 520524.
  • 20
    Di Fazio I, Motta M, Musumeci S, Neri S, Pistone G, Malaguarnera M. Efficacy of human recombinant erythropoietin plus IFN-alpha in patients affected by chronic hepatitis C. J Interferon Cytokine Res 2004; 24: 594599.
  • 21
    Lebray P, Nalpas B, Vallet-Pichard A, Broissand C, Sobesky R, Serpaggi J, et al. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus. Antivir Ther 2005; 10: 769776.
  • 22
    Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118124.
  • 23
    Neumann U, Puhl G, Bahra M, Berg T, Langrehr JM, Neuhaus R, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2b plus ribavirin. Transplantation 2006; 82: 4347.
  • 24
    Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. HEPATOLOGY 2005; 41: 275279.
  • 25
    Younossi ZM, Ong JP, Collantes R, Assmann JS, Sjogren R, Sjogren M, et al. Darbepoietin alfa for ribavirin-induced anemia in patients with chronic hepatitis C treated with pegylated interferon and ribavirin: a preliminary analysis (abstract). Gastroenterology 2004; 126( suppl 2): 83.
  • 26
    Castells L, Vargas V, Allende H, Bilbao I, Lazaro JL, Margarit C, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 5359.
  • 27
    Neff GW, Montalbano M, O'Brien CB, Nishida S, Safdar K, Bejarano PA, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78: 13031307.
  • 28
    Van Thiel DH, Faruki H, Friedlander L, Fagiuoli S, Caraceni P, Molloy PJ, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995; 42: 907912.
  • 29
    Gopal DV, Rabkin JM, Berk BS, Corless CL, Chou S, Olyaei A, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001; 7: 181190.
  • 30
    Bunn HF. Drug-induced autoimmune red-cell aplasia. N Engl J Med 2002; 346: 522523.
  • 31
    Stravitz RT, Chung H, Sterling RK, Luketic VA, Sanyal AJ, Price AS, et al. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol 2005; 100: 14151419.
    Direct Link:
  • 32
    Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams S, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 14031408.
  • 33
    Balan V, Schwartz D, Wu GY, Muir AJ, Ghalib R, Jackson J, et al. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. Am J Gastroenterol 2005; 100: 299307.
    Direct Link:
  • 34
    Ottmann OG, Hoelzer D, Gracien E, Ganser A, Kelly K, Reutzel R, et al. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995; 86: 444450.
  • 35
    Hubel K, Engert A. Clinical applications of granulocyte colony-stimulating factor: an update and summary. Ann Hematol 2003; 82: 207213.
  • 36
    Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. HEPATOLOGY 2002; 36: 12731279.
  • 37
    Renou C, Harafa A, Bouabdallah R, Demattei C, Cummins C, Rifflet H, et al. Severe neutropenia and post-hepatitis C cirrhosis treatment: is interferon dose adaptation at once necessary? Am J Gastroenterol 2002; 97: 12601263.
    Direct Link:
  • 38
    Cooper CL, Al-Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006; 42: 16741678.
  • 39
    Puoti M, Babudieri S, Rezza G, Viale P, Antonini NG, Maida I, et al. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther 2004; 9: 627630.
  • 40
    Steensma DP, Loprinzi CL. Erythropoietin use in cancer patients: a matter of life and death? J Clin Oncol 2005; 23: 58655868.
  • 41
    Homoncik M, Jilma-Stohlawetz P, Schmid M, Ferlitsch A, Peck-Radosavljevic M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2004; 20: 437443.
  • 42
    Spiegel BM, Chen K, Chiou CF, Robbins S, Younossi ZM. Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. Clin Gastroenterol Hepatol 2005; 3: 10341042.
  • 43
    Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 2006; 57: 813.